Amgen beats Q1 expectations, issues solid full-year outlook

Investing.com - Amgen Inc (NASDAQ: AMGN) reported better-than-expected first-quarter results, driven by strong demand for its products globally.

The biotechnology company posted adjusted earnings per share of $4.90, surpassing analyst estimates of $4.29. Revenue rose 9% YoY to $8.15 billion, slightly above the consensus forecast of $8.09 billion.

"Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects," said Robert A. Bradway, chairman and chief executive officer.

Product sales grew 11%, primarily driven by 14% volume growth, partially offset by 6% lower net selling price. U.S. sales increased 14%.

Fourteen products delivered at least double-digit sales growth in the quarter, including Repatha, BLINCYTO, and TEZSPIRE. The company’s newly launched IMDELLTRA generated $81 million in sales.

For the full year 2025, Amgen said it expects adjusted EPS of $20.00-$21.20, versus the consensus of $20.63, and revenue of $34.3-$35.7 billion, versus the consensus of $35.102 billion.

The company generated $1.0 billion of free cash flow in Q1, up from $0.5 billion in the same period last year.

Amgen’s shares were flat in after-hours trading following the earnings release.

You May Also Be Interested In

• The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
• Kepler Cheuvreux upgrades SEGRO to buy, lifts target price by nearly 30%
• South Plains Financial Inc. (SPFI) Tops Q2 EPS by 1c